Most cited papers from Tesaro (United States)

Tesaro (United States)

What are the most cited papers from Tesaro (United States)?

The most cited paper from Tesaro (United States) is "Oncogenic Signaling Pathways in The Cancer Genome Atlas" (Francisco Sánchez-Vega et al., 2018), with 3,452 citations. Next come "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer" (2,495) and "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer" (2,318).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 17 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Oncogenic Signaling Pathways in The Cancer Genome Atlas Francisco Sánchez-Vega et al. · Cell Open access779 authors	Apr 2018	3,452
2	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza et al. · New England Journal of Medicine Open access	8 Oct 2016	2,495
3	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n et al. · New England Journal of Medicine Open access	28 Sep 2019	2,318
4	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Theo Knijnenburg et al. · Cell Reports Open access763 authors	Apr 2018	1,249
5	Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma Panagiotis A. Konstantinopoulos et al. · JAMA Oncology Open access	13 Jun 2019	579
6	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial Kathleen N. Moore, Angeles Alvarez Secord, Melissa Ann Geller et al. · The Lancet Oncology	Apr 2019	545
7	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer Shaveta Vinayak, Sara M. Tolaney, Lee Steven Schwartzberg et al. · JAMA Oncology Open access	13 Jun 2019	457
8	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer Anniina Färkkilä et al. · Nature Communications Open access	19 Mar 2020	343
9	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis Ila J. Datar et al. · Clinical Cancer Research Open access	3 May 2019	336
10	The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake Álvaro de Mingo Pulido, Kay Hänggi, Daiana Pamela Celias et al. · Immunity Open access	11 May 2021	270
11	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models Zebin Wang, Kaiming Sun, Yonghong Xiao et al. · Scientific Reports Open access	12 Feb 2019	265
12	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy Charlie Gourley, Judith Balmañà, Jonathan A. Ledermann et al. · Journal of Clinical Oncology Open access	3 May 2019	200
13	Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial Josep M. del Campo et al. · Journal of Clinical Oncology Open access	7 Jun 2019	196
14	Safety and dose modification for patients receiving niraparib Jonathan S. Berek et al. · Annals of Oncology Open access	10 May 2018	189
15	A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models Kaiming Sun, Keith W. Mikule, Zebin Wang et al. · Oncotarget Open access	14 Dec 2018	188
16	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial Lee Steven Schwartzberg, Manuel Modiano, Bernardo Leon Rapoport et al. · The Lancet Oncology	10 Aug 2015	154
17	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials Bernardo Leon Rapoport, Martin Robert Chasen, Cesare Gridelli et al. · The Lancet Oncology	10 Aug 2015	142
18	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial Amit M. Oza, Ursula A. Matulonis, Susanne Malander et al. · The Lancet Oncology	17 Jul 2018	126
19	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Benedetta Giovanna Pellegrino et al. · Cancer Research Open access	16 Feb 2022	100
20	The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma Benjamin J. Chen, Dashnamoorthy Ravi, Pallavi Kanwar Galera et al. · Oncotarget Open access	12 Mar 2019	88
21	Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer Chia‐Chi Hsu, Bin-Chi Liao, Wei‐Yu Liao et al. · Journal of Thoracic Oncology Open access	23 Sep 2019	86
22	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma Diwakar Davar, Hong Wang, Joë-Marc Chauvin et al. · Journal of Clinical Oncology Open access	25 Oct 2018	85
23	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma Mariam M. AlHilli, Marc A. Becker, S. John Weroha et al. · Gynecologic Oncology Open access	10 Sep 2016	77
24	Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy Paul Joseph Hesketh, Ian D. Schnadig, Lee Steven Schwartzberg et al. · Cancer Open access	13 May 2016	71
25	Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development Jing Wang, Suhasini Iyer, Paul J. Fielder et al. · Biopharmaceutics & Drug Disposition	13 Apr 2015	70
26	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients Andrew D.J. Pearson et al. · European Journal of Cancer Open access	23 Jan 2020	68
27	Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC) Bernardo Leon Rapoport, Daniel T. T. Chua, Allen Poma et al. · Supportive Care in Cancer	4 May 2015	66
28	TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo Srimoyee Ghosh, Geeta Sharma, Jon Travers et al. · Molecular Cancer Therapeutics	26 Dec 2018	63
29	Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition Gayathri Srinivasan, Gurjit Singh Sidhu, Elizabeth A. Williamson et al. · Cancer Chemotherapy and Pharmacology Open access	29 Jul 2017	62
30	Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study Nicholas C. Turner et al. · Clinical Cancer Research Open access	22 Jul 2021	55
31	Increased risk of brain metastases in ovarian cancer patients with BRCA mutations Elena Ratner, Mohan V. Bala, Melinda Louie-Gao et al. · Gynecologic Oncology	12 Mar 2019	55
32	2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays) Lauren F. Stevenson et al. · Bioanalysis	29 Nov 2018	55
33	Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial Michel Fabbro, Kathleen N. Moore, Anne Dørum et al. · Gynecologic Oncology Open access	9 Jan 2019	48
34	Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy Bernardo Leon Rapoport, Lee Steven Schwartzberg, Martin Robert Chasen et al. · European Journal of Cancer Open access	4 Feb 2016	48
35	Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer Ana Oaknin, Linda Duska, Ryan Joseph Sullivan et al. · Gynecologic Oncology	Jun 2019	45
36	Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. Lee Steven Schwartzberg, Brooke S. Harrow, Lincy Subha Lal et al. · PubMed Open access	18 Sep 2015	44
37	NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim Jeffrey J. Kirshner, Maxwell C. McDonald, Flavio Kruter et al. · Supportive Care in Cancer Open access	16 Nov 2017	41
38	Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients L. van Andel, Hilde Rosing, Z. Zhang et al. · Cancer Chemotherapy and Pharmacology Open access	17 Oct 2017	40
39	Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer L. van Andel, Z. Zhang, Sharon M. Lu et al. · Investigational New Drugs Open access	16 Mar 2017	40
40	Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial Ursula A. Matulonis et al. · Journal of Clinical Oncology Open access	13 Sep 2019	37
41	Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts Ádám Póti, Kinga Berta, Yonghong Xiao et al. · British Journal of Cancer Open access	Nov 2018	28
42	Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer Karen L. Reckamp · Journal of the National Comprehensive Cancer Network Open access	May 2018	28
43	The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer Kathleen N. Moore, Zhi-Yi Zhang, Shefali Agarwal et al. · Cancer Chemotherapy and Pharmacology Open access	10 Jan 2018	28
44	Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme Matthew M. Hamilton et al. · Journal of Medicinal Chemistry Open access	22 Jul 2021	27
45	The Impact of Rehabilitation-oriented Virtual Reality Device in Patients With Ischemic Stroke in the Early Subacute Recovery Phase: Study Protocol for a Phase III, Single-Blinded, Randomized, Controlled Clinical Trial N A Rafi Ahmed et al. · Journal of Central Nervous System Disease Open access	2020	25
46	Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine L. van Andel, Z. Zhang, Sharon M. Lu et al. · Journal of Chromatography B Open access	19 Nov 2016	25
47	Real-World Adverse Events with Niraparib 200 mg/Day Maintenance Therapy in Ovarian Cancer: A Retrospective Study Jack Ray Gallagher, Kylee Heap, Susan L. Carroll et al. · Future Oncology Open access	11 Nov 2019	24
48	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models Maria J. Sambade, Amanda E.D. Van Swearingen, Marni B. McClure et al. · Neuro-Oncology Advances Open access	May 2019	24
49	Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer Ana Oaknin, Susan L. Ellard, Charles Alexander Leath et al. · Annals of Oncology Open access	Oct 2018	23
50	A review of in vivo and in vitro aspects of alcohol-induced dose dumping Susan D’Souza, Stephen P. Mayock, Alger D. Salt · AAPS Open Open access	7 Jun 2017	23

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.